Published

Patients with bipolar II disorder benefit from single dose of psilocybin

A single 25-mg dose of psilocybin resulted in improvement in depressive symptoms in all 15 participants in an open-label nonrandomized trial enrolling adults with bipolar II disorder. Twelve of the 15 participants met response and remission criteria at the study's 12-week endpoint.

Open source BibTeX RIS

Bibliographic context

Journal: The Brown University Psychopharmacology Update
Date: 2024-03-03
Source: OpenAlex
DOI: 10.1002/pu.31143
PubMed: Unavailable

Authors

Watch author

Topics and keywords

psilocybin Depression Pharmacology Clinical Trial Psilocybin Bipolar disorder Medicine Pharmacology Neuroscience Psychology Psychiatry Hallucinogen Cognition Psychedelics and Drug Studies Mental Health and Psychiatry Sexuality Behavior and Technology

Citation graph

0 referenced DOIs found in stored source metadata. 1 indexed paper cite this DOI.

Open citation network

Indexed papers citing this DOI

Patients with bipolar II disorder benefit from single dose of psilocybin2024-03-03

Related papers

Neurobiology of psilocybin: a comprehensive overview and comparative analysis of experimental modelsFrontiers in Systems Neuroscience · 2025-08-04 Exploring the molecular basis of treatment-resistant depression: Discoveries from a rat model and psilocybin therapyNeuroscience Applied · 2023-12-31 Amygdala response to emotional faces following acute administration of psilocybin in healthy individualsNeuroscience Applied · 2023-12-29 Acute psilocybin increased cortical activities in ratsFrontiers in Neuroscience · 2023-05-22 Acute psilocin increased cortical activity in ratFrontiers in Neuroscience · 2026-02-03 The Effect of Magic Mushroom ( Psilocybe azurescens ) on Social Interaction, Anxiety- and Depressive-Like Behaviors in Male Rats; the Role of Neuroinflammation, Oxidative Stress, and Neurotrophic FactorsJournal of Neuroscience Research · 2025-12-31 Single-dose psilocybin rapidly and sustainably relieves allodynia and anxiodepressive-like behaviors in mouse models of chronic painNature Neuroscience · 2025-10-01 Long-term effects of single-dose psilocybin and psychedelic mushroom extract in the SAPAP3 model of OCD-like behaviorNeuroscience Applied · 2024-12-31